



ELSEVIER

Contents lists available at ScienceDirect

International Journal of Infectious Diseases

journal homepage: www.elsevier.com/locate/ijid

Short Communication

SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV



Alessandra Vergori^{1,*}, Alessandro Cozzi-Lepri², Alessandro Tavelli³, Valentina Mazzotta¹, Anna Maria Azzini⁴, Roberta Gagliardini¹, Ilaria Mastroianni¹, Alessandra Latini⁵, Giovanni Pellicanò⁶, Lucia Taramasso⁷, Francesca Ceccherini-Silberstein⁸, Maddalena Giannella⁹, Evelina Tacconelli⁴, Giulia Marchetti¹⁰, Antonella d'Arminio Monforte¹⁰, Andrea Antinori¹, On behalf of Vax ICONA ORCHESTRA Study group

¹ HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

² Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK

³ Icona Foundation, Milan, Italy

⁴ Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy

⁵ STI/HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy

⁶ Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", University of Messina, Messina, Italy

⁷ Infectious Diseases Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

⁸ Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy

⁹ Infectious Diseases Unit, IRCCS University Hospital of Bologna, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy

¹⁰ Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy

ARTICLE INFO

Article history:

Received 15 January 2024

Revised 15 April 2024

Accepted 17 April 2024

Keywords:

HIV
mRNA SARS-CoV-2 vaccine
CD4 count
CD8 count
HIV RNA
Viro-immunological changes

ABSTRACT

Objectives: To investigate whether SARS-CoV-2 messenger RNA (mRNA) vaccination has an impact on HIV-related viro-immunological parameters.

Methods: People with HIV (PWH) in the VAXICONA-ORCHESTRA cohort who received one or more doses of SARS-CoV-2 mRNA vaccine and for whom paired measures of immuno-virological markers (viral load, clusters of differentiation [CD]4, and CD8 count 1 month before and after a vaccine dose [VD]) were available were included. Paired *t*-test and generalized estimating equation linear regression analyses were used to study changes over ± 1 month around the VD. Subgroup analyses were performed.

Results: A total of 510 PWH were enrolled: the median age was 55 years (interquartile range 46–60 years), the CD4 and CD8 count were 489 (287–719) and 790 (59–1104) cells/mm³, respectively, and 81% received three VDs. After a median of 28 (3–53) days from VD, CD4 count increased by +15 cells/mm³ (SD ± 129.7 , $P = 0.001$) and CD8 by +12 (± 250.5 , $P = 0.199$) and the viral load decreased by $-0.11 \log_{10}$ (± 0.88 , $P = 0.001$). Similar results were observed after restricting the analysis to viro-suppressed PWH, with CD4 ≤ 200 /mm³, more than 6 months of antiretroviral therapy before VD and after excluding previous COVID-19.

Conclusions: A small significant increase in CD4 count and a negligible drop in HIV RNA were observed. Our findings are consistent with the hypothesis that SARS-CoV-2 mRNA vaccine can prime CD4 T spike-specific cells, even in the more immuno-compromised PWH.

© 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Introduction

A great body of evidence reassures the safety of SARS-CoV-2 vaccination in people with HIV (PWH), who can mount a satisfactory immune response [1] comparable to those of the general

* Corresponding author.

E-mail address: alessandra.vergori@inmi.it (A. Vergori).

population, except for cases with a low clusters of differentiation (CD)4⁺ T-cell count recovery [1]. Notwithstanding, some concerns emerged because of the possible detrimental effects of SARS-CoV-2 vaccination on HIV viral load (VL) and CD4 and CD8 T cells, although most of the evidence is anecdotal or comes from limited case series with conflicting results [2–5]. In addition, some previous studies have found transient increases in VL after flu, *Streptococcus pneumoniae*, and hepatitis B virus vaccination, whereas other papers have shown no effect [6–8].

Whether there is immuno-virological impairment associated with SARS-CoV-2 messenger RNA (mRNA) vaccination remains to be established.

Methods

Study population

The criteria to be included in the present analyses were the following: (i) enrolled in the Vax ICONA ORCHESTRA cohort, (ii) have received at least one vaccine dose (VD) of SARS-CoV-2 mRNA vaccine, and (iii) have been tested for immuno-virological markers (VL, CD4 count, and CD8 count approximately ± 1 month before and after any VD).

Details of the design of the Vax ICONA ORCHESTRA cohort are described in the supplementary appendix. The study has been approved centrally by the ethics committee of INMI Lazzaro Spallanzani for Italian centers and by the ethics committees of all participating centers outside Italy. The study was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects involved.

Endpoints

We evaluated the changes in CD4 count, CD8 count (natural scale), and HIV VL (\log_{10} scale) over 1 month around each VD. We also reported the percentage of marker pairs in whom VL went from ≤ 50 copies/ml before the VD to VL > 50 copies/ml after the VD and *vice versa*.

Statistical analysis

The main characteristics of the study population were described overall and according to the time elapsed from antiretroviral therapy (ART) initiation to the VD.

Dot plots were used to show the distribution of markers before VD (T0) and after VD (T1) and their change. A paired *t*-test was used to test the mean difference against the null hypothesis of no change 1 month after each VD. The McNemar test was used to evaluate the change in the proportion of VL suppression before and after VD. To account for the extra correlation of marker pairs coming from the same participant, we also conducted a generalized estimating equation linear regression model.

Several sensitivity descriptive analyses were done after restricting to the following subsets of markers pairs: (i) those with pre-VD value > 6 months after starting ART, (ii) with pre-VD VL ≤ 50 copies/ml, (iii) with pre-VD CD4 count ≤ 200 cells/mm³, (iv) no evidence of COVID-19, and (v) after restricting to pairs measured around the first VD.

Results

A total of 510 PWH included the following: 19% females, median age 55 years (interquartile range 46–60), and 81% Caucasian. Overall, 97% of participants were on ART, the CD4 count nadir was

83 (30–185) cells/mm³, the CD4 count before the first VD was 489 cells/mm³ (287–719 cells/mm³, higher in those who started ART ≥ 6 months before vaccination [510 (323–741) cells/mm³] vs < 6 months (L6m) (397 [198, 678]; $P < 0.001$), the median CD8 count was 790 (594–1104) cells/mm³, with no evidence for a difference between the two groups ($P = 0.139$); as expected, HIV RNA ≤ 50 copies/ml was more frequently found in those who started ART ≥ 6 months than in those who started ART < 6 months (93% vs 80%, $P < 0.001$, Table S1).

A comparison between the characteristics of the study population and those of PWH in the whole cohort who were excluded from the analyses is reported in Table S2.

The included individuals contributed 723 marker pairs measured ± 1 month of a VD. The median time between the pre- and post-VD values was 28 (3–53) days. Overall, 461 (63%) pairs were around the first dose, 230 (32%) around the second dose, and only 33 (4.5%) around the third dose (Table S3).

Changes of CD4 and CD8 and HIV RNA

Figure 1 shows the median, interquartile range, and the whole CD4 and CD8 count distribution before and after vaccination and their changes. The CD4 count significantly increased by a mean of $+15.5$ cells/mm³ (SD ± 129.7 , paired *t*-test $P = 0.001$) and CD8 by $+12.0$ (± 250.5 , $P = 0.199$) (Table 1). In contrast, the VL decreased by $-0.11 \log_{10}$ (± 0.88 , $P = 0.001$). The results were similar after restricting the analysis to pairs measured around the first VD (Table S4). The significance of these results was confirmed in the generalized estimating equation analysis (Table S5).

Similar results were observed after controlling for potential sources of confounding by stratification, as described in the Methods (Table 1).

Finally, among PWH with VL ≤ 50 copies/ml before VD, only 2.2% (14 of 639) had VL > 50 copies/ml after VD and in 36% of those with VL > 50 copies/ml VD achieved a VL ≤ 50 copies/ml (McNemar test $P = 0.10$). Among those with an elevation of VL to a value > 50 copies/ml after VD, in 10 of 14 (71%), the subsequent VL was back to < 50 copies/ml, without a change in ART.

Table 1

Overall mean (SD) changes from pre- to post-VD and paired *t*-test results and in specific subsets.

Analysis of marker changes - crude analysis				
HIV-marker	N	Mean	SD	P-value ^a
Overall results				
HIV-RNA	710	-0.11	0.88	0.001
CD4 count	723	15.47	126.1	0.001
CD8 count	720	12.00	250.5	0.199
Pre-VD VL less than 50				
HIV-RNA	639	-0.01	0.76	
CD4 count	641	14.39	127.8	
CD8 count	638	8.28	238.7	
Pre-VD CD4 count less than 200				
HIV-RNA	99	-0.37	1.05	
CD4 count	102	26.36	65.35	
CD8 count	102	42.74	224.2	
ART initiation > 6 months				
HIV-RNA	529	-0.06	0.81	
CD4 count	539	13.48	127.5	
CD8 count	536	2.55	218.8	
No previous SARS-CoV-2 infection				
HIV-RNA	672	-0.11	0.90	
CD4 count	684	12.67	125.4	
CD8 count	681	9.81	253.4	

ART, antiretroviral therapy; CD, cluster of differentiation; VD, vaccine dose; VL, viral load.

^a Paired *t*-test.




Figure 1. Median changes before and after viral load of CD4 count (a) and CD8 (b) count. CD, cluster of differentiation.

Discussion

To the best of our knowledge, ours is the first analysis evaluating the immune-virological changes after any mRNA SARS-CoV-2 VD in a large cohort of PWH during a broad vaccination campaign. We found no evidence for a clinically significant impact of SARS-CoV-2 mRNA vaccination on CD4 and CD8 counts or HIV RNA over a mean window of 28 days around VDs. Indeed, although a statistically significant increase in CD4 count and drop in HIV RNA were observed, the magnitude of the changes was of negligible clinical significance. The results were similar to several sensitivity analyses controlling for close initiation of ART, evidence of natural infection, and immuno-virological status before vaccination.

Importantly, our findings do not confirm previous studies showing a potential detrimental effect of SARS-CoV-2 vaccination on CD4 count. Regarding VL, conflicting results were previously reported. One study found a marginal increase in the rate of detectable viremia after 4 weeks after the second VD [9], and two others reported no changes in VL after two VDs [4,5]. Moreover, 1 month after each VD, the proportion of participants with detectable VL remained stable, with no participant experiencing virologic failure. In addition, in our analysis, only 2% of participants appeared to have a VL elevation after vaccination. In 71% of these, the VL returned to a value <50 copies/ml without a change in ART.

Our analysis has some limitations. First, we did not have a control group of unvaccinated PWH with marker changes measured within a month after the same time from ART initiation to compare with. Second, we did not investigate the potential effect of vaccination on the size of the viral reservoir, although a recent study carried little evidence for such an association [10]. Furthermore, the changes were evaluated over an average of 28 days, which may be too long to detect dose-elicited variations. Finally, the characteristics of the included sample differ from those of the whole cohort; therefore, we cannot rule out selection bias.

The strength of our study is the high number of paired pre- and post-vaccination markers and the confirmation of the same results in different settings, including the recent start of ART and different strata of CD4.

In conclusion, our analysis could not confirm the data of previous reports showing a detrimental effect of SARS-CoV-2 vaccination on HIV markers. In contrast, our results are consistent with the hypothesis that mRNA vaccines might be able to rapidly prime

CD4 spike-specific cells independently of ART, also in immuno-suppressed PWH, and CD8 because it has been previously demonstrated by a clinical case of HIV/SARS-CoV-2 co-infection, in which a reversal of CD8 T-cell exhaustion [11], commonly observed in PLWH [12], or enhanced CD8 T-cell effector function is observed. Moreover, the interplay between CD8 enhancement and transient decreases of HIV RNA found in this study might be similar to what is observed in elite controllers, namely, that HIV-specific CD8 T cells from elite controllers have an increased capacity to produce multiple antiviral cytokines after peptide stimulation (poly-functionality) and could have increased expansion capacity and increased expression of the effector functions and thus an enhanced antiviral function [13].

Further studies are needed to confirm that there was no immuno-virological impairment associated with SARS-CoV-2 mRNA vaccination.

Declarations of Competing Interest

The authors have no competing interests to declare.

Funding

The ORCHESTRA project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 101016167. Alessandro Cozzi-Lepri's work has been co-funded by the EuCARE project funded by the EU under the HORIZON Europe program GA n. 101046016.

Acknowledgments

Orchestra Project coordinator: Evelina Tacconelli; Orchestra WP4 coordinator: Maddalena Giannella; Vax-Icona Orchestra Scientific coordinators: Antonella d'Arminio Monforte, Andrea Antinori; Data coordinators and statistics: Alessandro Tavelli, Alessandra Rodanò, Iuri Fanti, Alessandro Cozzi-Lepri; Participating Centers Italy: Andrea Costantini (Ospedali Riuniti, Ancona); Pierluigi Viale, Maddalena Giannella, Lorenzo Marconi, Leonardo Calza, Natascia Carroccia, Michela Di Chiara, Francesca Fani (IRCCS AOU di Bologna, Bologna); Sergio Lo Caputo, Sergio Ferrara (Ospedali Riuniti, Foggia); Miriam Lichtner, Giulia Mancaralla, Laura Fondaco, Anna Carraro (Ospedale SM Goretti, Latina); Stefania Picconi, Silvia Pontiggia, Chiara Molteni (ASST Lecco, Lecco); Giuseppe

Nunnari, Giovanni Pellicanò (AOU Gaetano Martino, Messina); Giuliano Rizzardini, Maria Vittoria Cossu (ASST FBF-Sacco, Milano); Giulia Marchetti, Nicole Gemignani, Valeria Bono, Ylenia D'Errico, Daniela Campisi, Walter De Francesco, Luigi Pantaleo (ASST Santi Paolo e Carlo, Milano); Vincenzo Sangiovanni, Francesco M Fusco, Nadia Sangiovanni (AORN Ospedali dei Colli, Napoli); Antonio Cascio, Marcello Trizzino (Policlinico P. Giaccone, Palermo); Stefania Cicalini, Alessandra Vergori, Chiara Salis, Jessica Paulicelli, Valentina Mazzotta, Simone Lanini, Giuseppina Giannico, Angela D'Urso, Marisa Fusto (INMI L. Spallanzani IRCCS, Roma); Alessandra Latini, Aldo Morrone, Fulvia Pimpinelli, Anna Pacifici (IFO-Regina Elena-San Gallicano, Roma); Giordano Madeddu, Andrea De Vito (AOU di Sassari, Sassari); Evelina Tacconelli, Anna Azzini, Elda Righi, Assunta Sartor, Giulia Belli, Concetta Sciammarella (AOUI di Verona, Verona); Argentina: Gabriel Levy-Hara (Universidad de Buenos Aires, Buenos Aires); Spain: Jesus Rodriguez Baño, Zaira Palacios, Giulia Caponcello (Hospital Virgen Macarena, Seville).

Author contributions

Vergori A, Antinori A, D'Arminio A, Cozzi Lepri A, Tavelli A: conception and design of the study. Tavelli A, Mazzotta V, Mas-trorosa I, Gagliardini R, Azzini AM, Latini A, Pellicanò G: acquisition of data. Cozzi Lepri A: data analysis. Cozzi Lepri A, Vergori A, Antinori A, Tavelli A, D'Arminio A interpretation of data. Vergori A: drafting the article. Vergori A, Antinori A, D'Arminio A, Tacconelli E, Marchetti G, Gianella M, Taramasso L, Ceccherini-Silberstein F: revising it critically for important intellectual content. All authors: final approval of the version to be submitted.

Access to data

Data will be available upon reasonable request to the corresponding author.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.ijid.2024.107065](https://doi.org/10.1016/j.ijid.2024.107065).

References

- [1] Levy I, Rahav G. The effect of HIV on COVID-19 vaccine responses. *Curr Opin HIV AIDS* 2023;**18**:135–41. doi:[10.1097/COH.0000000000000790](https://doi.org/10.1097/COH.0000000000000790).
- [2] Bozzi G, Lombardi A, Ludovisi S, Muscatello A, Manganaro L, Cattaneo D, et al. Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272. *Int J Infect Dis* 2021;**113**:125–6. doi:[10.1016/j.ijid.2021.10.021](https://doi.org/10.1016/j.ijid.2021.10.021).
- [3] Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. *Clin Microbiol Infect* 2021;**27**:1851–5. doi:[10.1016/j.cmi.2021.07.031](https://doi.org/10.1016/j.cmi.2021.07.031).
- [4] Fusco FM, Carleo MA, Sangiovanni N, D'Abbraccio M, Tambaro O, Borrelli F, et al. Does COVID-19 vaccination with BNT162b2 influence HIV-related immunological and virological markers? Data from 235 persons living with HIV at Cotugno hospital, Naples, Italy: immune response after second and third doses, and influence on immunovirological markers. *Viral Immunol* 2023;**36**:360–5. doi:[10.1089/vim.2022.0182](https://doi.org/10.1089/vim.2022.0182).
- [5] Portillo V, Fedeli C, Ustero Alonso P, Petignat I, Mereles Costa EC, Sulstarova A, et al. Impact on HIV-1 RNA levels and antibody responses following SARS-CoV-2 vaccination in HIV-infected individuals. *Front Immunol* 2021;**12**:820126. doi:[10.3389/fimmu.2021.820126](https://doi.org/10.3389/fimmu.2021.820126).
- [6] Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. *J Infect Dis* 2000;**181**:522–31. doi:[10.1086/315260](https://doi.org/10.1086/315260).
- [7] Negredo E, Domingo P, Sambaat MA, Rabella N, Vázquez G. Effect of pneumococcal vaccine on plasma HIV-1 RNA of stable patients undergoing effective highly active antiretroviral therapy. *Eur J Clin Microbiol Infect Dis* 2001;**20**:287–8. doi:[10.1007/s100960100470](https://doi.org/10.1007/s100960100470).
- [8] Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. *Vaccine* 2000;**18**:1161–5. doi:[10.1016/s0264-410x\(99\)00389-8](https://doi.org/10.1016/s0264-410x(99)00389-8).
- [9] Matveev VA, Mihelic EZ, Benko E, Budyłowski P, Grocott S, Lee T, et al. Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV. *iScience* 2023;**26**:107915. doi:[10.1016/j.isci.2023.107915](https://doi.org/10.1016/j.isci.2023.107915).
- [10] Duncan MC, Omondi FH, Kinloch NN, Lapointe HR, Speckmaier S, Moran-Garcia N, et al. Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size. *AIDS* 2024. doi:[10.1097/QAD.0000000000003841](https://doi.org/10.1097/QAD.0000000000003841).
- [11] Shahbaz S, Sligl W, Osman M, Elahi S. Immunological responses in SARS-CoV-2 and HIV co-infection versus SARS-CoV-2 mono-infection: case report of the interplay between SARS-CoV-2 and HIV. *Allergy Asthma Clin Immunol* 2023;**19**:91. doi:[10.1186/s13223-023-00846-8](https://doi.org/10.1186/s13223-023-00846-8).
- [12] Shahbaz S, Dunsmore G, Koleva P, Xu L, Houston S, Elahi S. Galectin-9 and VISTA expression define terminally exhausted T cells in HIV-1 infection. *J Immunol* 2020;**204**:2474–91. doi:[10.4049/jimmunol.1901481](https://doi.org/10.4049/jimmunol.1901481).
- [13] Rutishauser RL, Trautmann L. CD8 + T-cell responses in HIV controllers: potential implications for novel HIV remission strategies. *Curr Opin HIV AIDS* 2022;**17**:315–24. doi:[10.1097/COH.0000000000000748](https://doi.org/10.1097/COH.0000000000000748).